Compare Twist Bioscience Corp (TWST) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs VNET Group Inc — how do they compare? Twist Bioscience Corp trades at $123.01 (market cap $7.82B), while VNET Group Inc trades at $7.53 (market cap $2.13B). The key difference: Twist Bioscience Corp is far larger — about 3.7× VNET Group Inc's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, VNET Group Inc nearer its low. Which is the better fit depends on your goals.
| TWST | VNET | |
|---|---|---|
Market Cap | $7.82B | $2.13B |
Sector | Health | Technology |
52-Week High | $124.88 | $14.03 |
52-Week Low | $24.16 | $6.29 |
Enterprise Value | $7.75B | $5.28B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $115.67, up 6.04% in the last session, with bullish technical signals from moving averages and a recent analyst upgrade. Revenue growth is strong, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, though the company remains unprofitable with negative net income margins. A recent $300 million public offering at $96 per share indicates capital raising for expansion.
The outlook is mixed: robust revenue growth and high analyst buy ratings (78.57%) support upside potential, but persistent losses, cash burn, and high valuation ratios pose significant risks. Investors should weigh growth prospects against financial sustainability concerns.
VNET trades at $7.33, up 4.56% in the last 24 hours, but technical indicators signal a bearish trend with RSI near overbought levels. The company reported a net loss of $256.77 million in 2025, with negative profit margins and ROE, though revenue grew to $9.95 billion. Recent news highlights strategic investor entry and AI-driven demand boosting wholesale data center growth, with Q2 2026 earnings due August 18, 2026.
The outlook remains mixed: analyst consensus is 62.5% buy with a 54% upside target, but persistent losses and high debt-to-asset ratio pose risks. Investment opportunity hinges on execution of capacity expansions and AI demand, while volatility from options trading and legal settlements adds uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
